SVN-114 selected as the lead candidate for PTSD discovery programme
Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company developing novel small-molecule therapeutics for high-burden central nervous system (‘CNS’) disorders,...
Read more










































